Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Debt to Equity (2021 - 2026)

Centessa Pharmaceuticals has reported Debt to Equity over the past 5 years, most recently at $0.21 for Q4 2025.

  • Quarterly Debt to Equity fell 22.98% to $0.21 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.21 through Dec 2025, down 22.98% year-over-year, with the annual reading at $0.21 for FY2025, 22.98% down from the prior year.
  • Debt to Equity was $0.21 for Q4 2025 at Centessa Pharmaceuticals, down from $0.36 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.36 in Q3 2025 and troughed at $0.15 in Q3 2024.
  • The 5-year median for Debt to Equity is $0.26 (2023), against an average of $0.25.
  • Year-over-year, Debt to Equity plummeted 46.84% in 2024 and then soared 140.1% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $0.15 in 2021, then soared by 34.83% to $0.21 in 2022, then soared by 54.33% to $0.32 in 2023, then fell by 15.33% to $0.27 in 2024, then dropped by 22.98% to $0.21 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Debt to Equity are $0.21 (Q4 2025), $0.36 (Q3 2025), and $0.32 (Q2 2025).